Brilliant Violet 605™ anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_BV605_013112
C57BL/6 mouse splenocytes were stained with CD3 PE and CD4 (clone RM4-5) Brilliant Violet 605™.
  • RM4-5_BV605_013112
    C57BL/6 mouse splenocytes were stained with CD3 PE and CD4 (clone RM4-5) Brilliant Violet 605™.
See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
100547 125 µL 152,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100548 50 µg 208,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/ml
µl sizes: lot-specific (please contact technical support for concentration and total µg amount)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Becton, Dickinson and Company and its affiliates. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. patent(s), pending patent applications and/or foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Bruder J, et al. 2017. Mol Ther Methods Clin Dev. 10.1016/j.omtm.2017.08.003. PubMed
  2. Ruscher R, et al. 2018. Bio Protoc. 8:e2757. PubMed
  3. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  4. Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed
  5. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  6. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  7. Ravussin A, et al. 2018. Cell Rep. 24:1085. PubMed
  8. Colliou N, et al. 2018. Gut Microbes. 9:279. PubMed
  9. Graham JB, et al. 2017. Curr Protoc Mouse Biol. 7:221. PubMed
  10. Han SJ et al. 2017. Immunity. 47(6):1154-1168 . PubMed
  11. Sharma M, et al. 2019. Immunometabolism. 1. PubMed
  12. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  13. Lyons J, et al. 2018. Sci Signal. 11. PubMed
  14. Trotta E, et al. 2018. Nat Med. 24:1005. PubMed
  15. Hartwig T et al. 2018. Cell reports. 25(13):3564-3572 . PubMed
  16. Bradley KC, et al. 2019. Cell Rep. 28:245. PubMed
  17. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  18. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  19. Wei SC, et al. 2019. Immunity. 50:1084. PubMed
  20. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  21. Gaylo‐Moynihan A et al. 2019. Immunity. 51(2):298-309 . PubMed
  22. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  23. Li X, et al. 2018. Cell Host Microbe. 24:847. PubMed
  24. Young A, et al. 2017. Cancer Res. 77:4684. PubMed
  25. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  26. Lee Y, et al. 2018. Antimicrob Agents Chemother. 62:00:00. PubMed
  27. Silva DA, et al. 2019. Nature. 565:186. PubMed
  28. Metzger R, et al. 2019. Front Oncol. 1.070138889. PubMed
  29. Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed
  30. Maniati E, et al. 2020. Cell Rep. 30:525. PubMed
  31. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  32. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  33. Klein JC, et al. 2017. Nat Commun. 8:14600. PubMed
  34. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  35. Wu B, et al. 2020. Int J Biol Sci. 16:1526. PubMed
  36. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  37. Camell CD, et al. 2020. Cell Metabolism. 30(6):1024-1039.e6.. PubMed
  38. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  39. Chao CC, et al. 2020. Cell. 179(7):1483-1498.e22.. PubMed
  40. Baker GJ, et al. 2020. Cell Syst. 0.647222222. PubMed
  41. Collins N, et al. 2020. Cell. 178(5):1088-1101.e15.. PubMed
  42. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
  43. Ge Y, et al. 2020. Mucosal Immunol. 13:34. PubMed
  44. Beom JY, et al. 2019. J Nat Prod. 82:2078. PubMed
  45. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  46. Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed
  47. Muppidi J, et al. 2015. J Exp Med. 212: 2213 - 2222. PubMed
  48. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  49. Jyh Liang Hor, William R. Heath, Scott N. Mueller 2017. Sci Rep. 7:41091. PubMed
  50. Ward E, Fu H, Marelli-Berg F 2017. Methods Mol Biol. 10.1007/978-1-4939-6931-9_15. PubMed
  51. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  52. Sharma M, et al. 2020. Circ Res. 127:335. PubMed
  53. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  54. Lovisa S, et al. 2020. Sci Signal. 13:00. PubMed
  55. Latif AL, et al. 2021. Nat Commun. 0.667361111. PubMed
  56. Webb LMC, et al. 2021. Aging Cell. 20:e13295. PubMed
  57. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  58. Tummers B, et al. 2020. Immunity. 52(6):994-1006.e8. PubMed
  59. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  60. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  61. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  62. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  63. Doron I, et al. 2021. Cell. 184(4):1017-1031.e14. PubMed
  64. Zhang S, et al. 2021. Cell. 184(8):2151-2166.e16. PubMed
  65. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  66. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  67. Pingili AK, et al. 2021. Cell Reports. 35(12):109285. PubMed
  68. Marangoni F, et al. 2021. Cell. . PubMed
  69. Wei Y, et al. 2021. Endocrinology. 162(8):. PubMed
  70. Prizant H, et al. 2021. Cell Reports. 36(6):109523. PubMed
  71. Sano T, et al. 2021. Cell Reports. 36(8):109608. PubMed
  72. Nascimento DC, et al. 2021. Immunity. :. PubMed
  73. Israelow B, et al. 2020. bioRxiv. . PubMed
  74. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
RRID
AB_11125962 (BioLegend Cat. No. 100547)
AB_2563054 (BioLegend Cat. No. 100548)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 2    Revision Date: 01/29/2013

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account